Alopecia

Posters suggest deuruxolitinib, a medication targeting specific cellular pathways, effectively promotes hair regrowth in patients with moderate to severe alopecia areata (AA) and results in minimal adverse events.

Baricitinib and other oral JAK inhibitors show promise as effective treatments for moderate-to-severe alopecia areata (AA), with fewer adverse effects compared with traditional options.

A study in San Bernardino County found no increased risks of alopecia areata (AA) after the COVID-19 vaccination but suggests further research into potential geographic and gender-based factors.

A study found baricitinib to be safe and effective for treating severe alopecia areata (AA) but expressed the need for more long-term trials to support these findings.

An expert survey using the eDelphi method pinpointed disease duration, treatment response, and mental health as crucial factors in a new multidimensional tool known as Alopecia Areata Severity and Morbidity Index (ASAMI), underlining the importance of personalized treatments for future research incorporating patient perspectives.

Women with alopecia areata (AA), especially those with severe symptoms and lower income, face significant financial burden managing the condition.

A Japanese study of alopecia areata (AA) found misalignment between patient and doctor perceptions of severity, limiting treatment options, and leading to dissatisfaction and unmet needs.

New research explores T cells and their signaling pathways in alopecia areata (AA), highlighting promising drug targets for future treatment.

Meta-analysis results identify high and low associations of various comorbidities like vitamin D deficiencies, ocular diseases, among others in patients with alopecia areata (AA), to promptly manage and improve treatment outcomes.

Baricitinib was found to be an effective treatment for patchy alopecia areata (AA), in a retrospective study, with most patients experiencing hair regrowth after 4 to 16 weeks of treatment.

Topical treatments and minoxidil solutions were found to be the most effective, safe, and affordable first-line options for treating pediatric AA.

A study from China found that tofacitinib was an effective treatment for alopecia areata (AA), with most patients achieving complete or partial hair regrowth and experiencing tolerable side effects.

A survey of pediatric dermatologists revealed that topical corticosteroids are the most common first-line treatment for children with alopecia areata, regardless of age or hair loss severity.

Black women with alopecia often struggle between concealing their hair loss and protecting their fragile scalps, all while seeking to express their cultural identity and build self-confidence.

A US study found alopecia areata (AA) is more common in non-White patients, likely due to underrepresentation in dermatology, leading to less consideration of AA as a diagnosis for non-White individuals.

People with alopecia areata who experience hair regrowth may also see improvements in their quality of life and mental health, according to a new study.

Baricitinib is more commonly prescribed by dermatologists for patients with alopecia in the United States and is projected to maintain a substantial market lead over ritlecitinib.

A new analysis evaluated the economic implications of alopecia on women and their families, with significant out-of-pocket expenses attributed to treatments and measures to conceal the condition.

The presence of cochlear dysfunction found in patients with alopecia areata (AA) suggests the need for more comprehensive assessment and management of hearing-related issues associated with AA.

Pharmacists play a role in advising patients with hair loss about self-management and proper application of over the counter products.

The distribution of eyebrow and eyelash hair loss in relation to the severity of scalp hair loss remains underexplored, and this study established baseline characteristics.

Patients with alopecia areata showed improved response rate with oral Janus kinase (JAK) inhibitors vs topical and sublingual JAK inhibitor administration.

Patients with alopecia areata were less likely to report decisional regret regarding treatment when dermatologists incorporated shared decision-making, with prescription of Janus kinase (JAK) inhibitors associated with the lowest decisional regret.

Despite decreasing trends observed in the global burden of alopecia areata, low-income countries and ​​Western Sub-Saharan Africa regions continue to exhibit rising incidence and disability-adjusted life-years rates.